Использование молекулярно-биологических методов для определения генетических нарушений при миелоидных лейкозах и мониторирования минимальной остаточной болезни

острый лейкоз, опухолевые маркеры, минимальная остаточная болезнь

1. Westbrook C. The molecular basis of neoplasia. In: Hematology: basic principles and practice. R. Hoffmann (ed). Philadelphia, Elsevier Inc.; 2005. p. 941—52.

2. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M. Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 2002;99:759—72.

3. Druker B.J., Talpaz M., Resta D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001;344:1031-7.

4. Schoh C., Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Onc Rep 2002;4:390—7.

5. Rowley J.D. A new consistent chromosome abnormality in chronic myeloid leukemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973;243:290—3.

6. Schnittger S., Kinkelin U., Schoh C. et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavourable subset of AML. Leukemia 2000;14:796—804.

7. Tiede C., Steudel C., Mohr B. et al. Analysis of FLT-3 activating mutations in 979 patients with acute myelogeneous leukemia: association with FAB-subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326—35.

8. Falini B., Nicoletti I., Martelli M. et al. Translocations and mutations involving the nucleophosmin (NPM-1) gene in lymphomas and leukemias. Haematologica 2007;92(4):519—32.

9. Jepsen K. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000;102;753—63.

10. Lian R.J. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001;20:7204-15.

11. Chen Z. Fusion between novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 1993;12:1161-7.

12. Nucifora G., Birn J., Erickson P. et al. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 1993;82:712-5.

13. Kusec R., Laczika K., Knob P. et al. AML/ETO fusion mRNA can be detected in remission blood samples of a patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:73.

14. Leroy H., Roumier C., Huyghe P. CEBPA point mutations in hematological malignancies, Leukemia 2005;19(3):329-34.

15. Gale R.E., Hills R., Pizzey A.R. et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005;106(12):3768-76.

16. Johanson B., Mootman A.V., Secker-Walker L.M. Derivative chromosomes of 11q23 translosations in hematological malignancies. European 11q23 Workshop participants. Leukemia 1998;12:828-33.

17. Fallini B., Nicoletti I., Martelli M. et al. Acute myeloid leukemia carryingcytoplas-mic/mutated nucleophosmin (NPMc+-AML): biologic and cinical features. Blood 2007;109(3):874-85.

18. Grimwade D., Walker H., Oliver F. et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood 1998;92:2322-33.

19. Leroy H., Roumier C., Huyghe P. CEBPA point mutations in hematological malignancies. Leukemia 2005;19;3:329-34.

20. Kusec R., Laczika K., Knob P. et al. AML/ETO fusion mRNA can be detected in remission blood samples of a patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735-9.

21. Liu Yin J.A., Toba K. Detection of minimal residual disease in acute myeloid leukemias: methodologies, clinical and biological significance. Br J Haematol 1999;106:578-90.

22. Kwong Y.L., Chan V., Wong K.F. et al. Use of polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 1995;75:821-5.

23. Satake N., Maseki N., Kozu T. et al. Dissapearance of AML1/MTG8 (ETO) fusion transcript in acute myeloid leukemia patients with t(8;21) in long term remission. Br J Haematol 1995;91:892-8.

24. Morschauser F., Cayuela J.M., Martini S. et al. Evaluation of minimal residual disease using reverse transcriptase reaction in t(8;21) acute myeloid leukemia: a multicentre study of 51 patients. J Clin Oncol 2000;18:788-94.

25. Toba K., Newton J., Nige S. et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with _ t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95:815-9.

26. Wattjes M.P., Krauter J., Nige S. et al. Comparision of nested competitive RT PCR and real time RT PCR for the detection of AML MTG8 fusion transcript in t(8;21) positive AML. Leukemia 2000;14(2):329-35.

27. Krauter J., Watties M.P., Nige S. et al. Real time detection and quantitation of AML MTG8 fusion transcript in t(8;21) positive AML patients. Br J Haematol 1999;107:80-5.

28. Caxton D.F., Liu P., Hsu H.B. et al. Detection of fusion transcript generated by the inversion of of 16 chromosome in acute myelogeneous leukemia. Blood 1994;83:750-6.

29. Poire J.M., Radford Weiss I., Rack K. et al. Detection of chromosome 16 CBFB/MYH11 transcript in myelomono-cytic leukemia. Blood 1995;85:1313-22.

30. Marcucci G., Galigiuri M.A., Dohner H. et al. Quantification of CBFB/MYH11 transcripts by real time PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001;15:1072-80.

31. Lo Coco F., Diverio D., Falini B. et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22.

32. Mandelli F., Diverio D., Avvisati G. et al. Molecular remission in PML/RARA positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.

33. Burnett K., Grimwade D., Solomon E. et al. Presenting white blood count and kinetics of molecular remission predict prognosis in acute promyelocetic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999;93:4131-43.

34. Diverio D., Rossi V., Avvisati G. et al. Early detection of relapse by prospective reverse transcriptase polymerase chain reaction of the PML/RARA fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter «AIDA» trial. Blood 1998;92:784-9.

35. Meloni G., Diverio D., Vignetti M. et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assesment by reverse transcriptase polymerase chain reaction of the PML/RARA fusion gene. Blood 1997;90:1321-5.

36. Grimwade D., Howe K., Langabeer S. et al. Minimal resisual disease in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PML/RARA and RARA/PML assessment in patients who ultimately relapsed. Leukemia 1996;10:61-6.

37. Tobal K., Liu Yin J.A. RT-PCR method with increased sensitivity shows persistence of PML/RARA transcripts in patients in long term remission of APL. Leukemia 1998;12:1349-54.

38. Tobal K., Moore H., Macheta M. et al. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML/RARA transcripts with sensitive competitive RT PCR method. Leukemia 2001;15:1060-5.

39. Cassinat B., Zassadowski F., Balitrand N. et al. Quantification of minimal residual disease in acute promyelocytic leukemia with t(15;17) using real-time PCR. Leukemia 2000;14:324-8.

40. Mitterbauer A., Manhalter C., Jager U. et al. Quantification of minimal residual disease in patients with acute promyelocytic leukemia (APL) by real time quantative PCR with specific fluorescent hybridization probes. Blood 2000;94(Suppl 1):313a.

41. Mitterbauer G., Zimmer C., Fonatsh C. et al. Monitoring of monimal residual disease in patients with MLL-AF9 positive acute myeloid leukenia by RT PCR. Leukemia 1999;13:519-24.

42. Mitterbauer G., Zimmer C., Pirc Danoewinata H. et al. Monitoring of monimal residual disease in patients with MLL-AF6 positive acute myeloid leukenia by reverse teranscriptase polymerase chain reaction. Br J Haematol 2001;109:622-8.

43. Okoshi Y., Shimizu S., Kojima H. et al. Detection of minimal residual disease in patient having acute myeloid leukemia with t(16;21)(p11;q22) treated ith allogeneic bone marrow transplantation. Acta Haematologica 2001;105:45-8.

44. Matsushita M., Ikeda H., Kizaki M. et al. Quantitative monitiring of the PRAME gene for the detection of minimal residual disease in leukemia Br J Haematol 2001;12:916-26.

45. Inoue K., Ogawa H., Yamagami T. et al. Long term follow -up of minimal residual disease in leukemia patients by monitoring WT-1 (Wilm's tumor gene) expression levels. Blood 1996;88:2267-78.

46. Gaiger A., Shmid D., Heinze G. et al. Detection of WT-1transcript by RT PCR in complete remission has no prognostic relevance in de novo acute myeloid lukemia. Leukemia 1998;12:1886-9.

47. Kreuzer K.A., Saborowski A., Lupberger J. et al. Fluorescent 5'exonu-clease assay for the absolute quantification of Wilm's tumor gene (WT-1) mRNA: implications for monitoring human leukemias. Br J Haematol 2001;14:313-8.

48. Kern W, Schoh C., Haferlach T., Schnttger S. Monitoring of minimal residual disease in acute myeloid leukemia. Clin Rev Oncol Hematol 2005;56:283-309.